We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Makena Gets a Second Chance to Impress FDA in Review Hearing
Makena Gets a Second Chance to Impress FDA in Review Hearing
The FDA is giving Covis Pharmaceuticals’ Makena — a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in high-risk women — another chance to prove itself.